Cormorant Asset Management’s Climb Bio CLYM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$24.2M Hold
2,106,000
– – 1.62% 20
2026
Q2
$27.5M Buy
+2,106,000
New +$21.8M 1.41% 21

Other funds holding CLYM

Cormorant Asset Management's CLYM Position: Q3 2026 in Review

Cormorant Asset Management held its Climb Bio (CLYM) position steady in Q3 2026 at 2,106,000 shares worth $24.2M. The position accounts for 1.62% of the portfolio, ranked #20.

Cormorant Asset Management first reported a position in CLYM in Q2 2026 and has held it in 2 quarters since. The position peaked at $27.5M in Q2 2026. 127 funds tracked by Wall St. Rank hold CLYM as of Q3 2026.

  • Cormorant Asset Management held 2,106,000 shares of Climb Bio worth $24.2M as of Q3 2026.
  • Cormorant Asset Management left its Climb Bio share count unchanged in Q3 2026.
  • Climb Bio made up 1.62% of Cormorant Asset Management's portfolio in Q3 2026, its #20 holding.
  • Cormorant Asset Management first reported a position in Climb Bio in Q2 2026 and has held it in 2 quarters since.
  • Cormorant Asset Management's Climb Bio position peaked at $27.5M in Q2 2026.
  • 127 funds tracked by Wall St. Rank held Climb Bio as of Q3 2026.

Based on Cormorant Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.